RxDoctor Payments Data

Zeeshan Khan, DO

Pulmonary Disease · Morrisville, PANPI 1821293556

Payments from drug & device makers

$4,177in general payments, 2019–2025

Across 99 payments — averaging $42.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Harmony Biosciences LLC$479
  • GSK$448
  • Jazz Pharmaceuticals Inc.$377
  • AstraZeneca$281
  • Boehringer Ingelheim$128
  • plus $580 from 12 others

What the payments were for

  • Consulting fees$1504%
  • Travel & lodging$1,83944%
  • Food & beverage$1,82344%
  • Education$3669%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,177 in reported general payments places this provider in the 65th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$171,451
Medicare patients
666
Services billed
1,439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter192$159,405
XywavSodium,calcium,mag,pot Oxybate11$142,452
Breztri AerosphereBudesonide/Glycopyr/Formoterol88$56,117
NucalaMepolizumab13$48,910
Stiolto RespimatTiotropium Br/Olodaterol Hcl48$42,369
Breo ElliptaFluticasone/Vilanterol71$41,477
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr60$38,197
Incruse ElliptaUmeclidinium Bromide76$35,669
Spiriva RespimatTiotropium Bromide31$24,050
Fluticasone-SalmeterolFluticasone Propion/Salmeterol116$14,990
Albuterol Sulfate HfaAlbuterol Sulfate409$11,126
Advair HfaFluticasone Propion/Salmeterol22$10,378
Spiriva HandihalerTiotropium Bromide15$9,365
Modafinil40$7,176
Bevespi AerosphereGlycopyrrolate/Formoterol Fum13$6,945

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$448$323,657412 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$128$66,41979 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$281$65,520112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Morrisville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →